Your browser is no longer supported. Please, upgrade your browser.
Settings
JAGX [NASD]
Jaguar Health, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own9.90% Shs Outstand127.91M Perf Week-3.05%
Market Cap165.10M Forward P/E- EPS next Y-0.18 Insider Trans0.00% Shs Float127.43M Perf Month-9.93%
Income-38.60M PEG- EPS next Q-0.02 Inst Own5.40% Short Float4.37% Perf Quarter-55.59%
Sales9.40M P/S17.56 EPS this Y88.90% Inst Trans2.86% Short Ratio0.53 Perf Half Y499.06%
Book/sh0.23 P/B5.52 EPS next Y-63.60% ROA-103.10% Target Price- Perf Year150.49%
Cash/sh0.06 P/C20.38 EPS next 5Y40.00% ROE-623.70% 52W Range0.19 - 4.47 Perf YTD55.83%
Dividend- P/FCF- EPS past 5Y- ROI-85.40% 52W High-71.59% Beta1.52
Dividend %- Quick Ratio1.10 Sales past 5Y105.10% Gross Margin65.10% 52W Low586.49% ATR0.14
Employees34 Current Ratio1.30 Sales Q/Q73.30% Oper. Margin- RSI (14)39.44 Volatility11.35% 10.70%
OptionableYes Debt/Eq0.94 EPS Q/Q78.10% Profit Margin- Rel Volume0.36 Prev Close1.16
ShortableYes LT Debt/Eq0.72 Earnings- Payout- Avg Volume10.56M Price1.27
Recom1.00 SMA20-9.22% SMA50-25.83% SMA2004.41% Volume3,827,199 Change9.48%
Jul-11-17Initiated Rodman & Renshaw Buy $2
May-14-21 04:30PM  
08:30AM  
May-11-21 08:30AM  
Apr-29-21 09:29AM  
08:00AM  
Apr-21-21 08:30AM  
Apr-19-21 08:30AM  
Apr-16-21 01:52PM  
Apr-15-21 08:30AM  
Apr-14-21 08:30AM  
Apr-08-21 08:30AM  
Apr-06-21 08:30AM  
Apr-02-21 04:15PM  
Mar-31-21 04:15PM  
Mar-30-21 08:30AM  
Mar-22-21 10:10AM  
Mar-15-21 08:30AM  
Mar-09-21 07:30AM  
Mar-05-21 12:26PM  
08:30AM  
Feb-25-21 10:24PM  
Feb-23-21 08:30AM  
Feb-19-21 04:40PM  
Feb-18-21 01:11PM  
08:30AM  
Feb-15-21 10:44AM  
Feb-12-21 01:54PM  
11:57AM  
Feb-09-21 08:30AM  
Feb-08-21 09:51AM  
Feb-04-21 08:42AM  
Feb-03-21 08:30AM  
Jan-26-21 08:45AM  
Jan-22-21 04:15PM  
02:26PM  
08:30AM  
Jan-21-21 08:30AM  
Jan-20-21 08:30AM  
Jan-15-21 08:30AM  
Jan-13-21 08:00AM  
08:00AM  
Jan-12-21 08:30AM  
Jan-11-21 08:30AM  
Jan-08-21 07:44PM  
Jan-06-21 08:30AM  
Jan-05-21 12:54PM  
09:55AM  
Dec-28-20 10:16AM  
Dec-24-20 10:02AM  
Dec-23-20 01:08PM  
08:30AM  
Dec-22-20 12:00PM  
Dec-15-20 08:30AM  
Dec-10-20 08:30AM  
Dec-07-20 08:30AM  
Dec-04-20 08:30AM  
Dec-01-20 10:26AM  
Nov-30-20 10:20AM  
08:30AM  
Nov-24-20 09:00AM  
Nov-16-20 08:00AM  
Nov-10-20 04:15PM  
Oct-29-20 08:30AM  
Oct-21-20 07:45AM  
Oct-20-20 08:30AM  
Oct-16-20 04:15PM  
Oct-15-20 08:30AM  
07:29AM  
Oct-14-20 08:30AM  
Oct-13-20 08:30AM  
Oct-12-20 10:19AM  
Oct-07-20 08:30AM  
Oct-06-20 08:30AM  
Oct-02-20 08:30AM  
Oct-01-20 08:30AM  
Sep-28-20 08:30AM  
Sep-24-20 08:30AM  
Sep-21-20 09:56AM  
Sep-16-20 08:30AM  
Sep-11-20 08:30AM  
Sep-10-20 08:30AM  
Sep-07-20 03:57PM  
Sep-03-20 08:30AM  
Sep-02-20 08:30AM  
Aug-19-20 08:30AM  
Aug-18-20 08:30AM  
Aug-14-20 04:15PM  
Aug-13-20 08:00AM  
Aug-11-20 08:30AM  
Aug-06-20 08:30AM  
Aug-03-20 01:14PM  
Jul-22-20 04:15PM  
08:30AM  
Jul-21-20 04:15PM  
Jul-20-20 08:30AM  
Jul-06-20 08:30AM  
Jul-02-20 08:30AM  
Jun-29-20 08:30AM  
Jun-25-20 06:55AM  
Jun-23-20 05:32PM  
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.